Abstract.
Objective and Design: We investigated the influence of cyclooxygenase inhibitors against the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in rheumatoid arthritis (RA) synoviocytes.¶Material: Synovial fibroblasts from RA patients were used.¶Treatment: The cells were treated with recombinant human interleukin 1β (rhIL-1β) (100 ng/ml) and/or indomethacin (0.1, 1, 10 μM) and diclofenac (0.1, 1, 10 μM) and/or prostaglandin E2 (PGE2) (1, 10 μM) for 72 h.¶Methods: The amounts of TIMP-1, proMMP-1 and PGE2 was measured by enzyme linked immunosorbent assay (ELISA). Statistical significance was tested with Student's t-test and Dunnett test.¶Results: RhIL-1β augments the production of TIMP-1 and proMMP-1 in synovial fibroblasts from RA patients, and this IL-1-induced production of TIMP-1 and proMMP-1 was further enhanced by treatment with the cyclooxygenase inhibitors, indomethacin and diclofenac. Exogenous PGE2 significantly suppresses indomethacin- and diclofenac-enhanced TIMP-1 and proMMP-1 production.¶Conclusion: PGE2 down-regulates the production of TIMP-1 and proMMP-1 in RA synoviocytes, and cyclooxygenase inhibitors regulate the production of TIMP-1 and proMMP-1 through the inhibition of PGE2 production in inflammation.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 2 March 1997; returned for revision 6 April 1997; accepted by M. Katori 31 May 1997
Rights and permissions
About this article
Cite this article
Takahashi, S., Inoue, T., Higaki, M. et al. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflamm. res. 46, 320–323 (1997). https://doi.org/10.1007/s000110050194
Issue Date:
DOI: https://doi.org/10.1007/s000110050194